ReP USP - Resultado da busca

Trabalho de evento-resumo periodico
Cardiovascular risk profile in young patients with epilepsy (2021)
Szczurkowska, Patrycja; Wolf, Jacek; Polonis, Katarzyna ; Becari, Christiane ; Pilarska, Ewa; Hoffmann, Michal; Chrostowska, Marzena; Mazurkiewicz-beldzinska, Maria; Narkiewicz, Krzysztof
Source: Journal of Hypertension. Conference titles: International SHR symposium SHR: genetics and disease model guided novel therapeutic target discovery in hypertension. Unidade: FMRP
Subjects: DOENÇAS CARDIOVASCULARES, EPILEPSIA, SISTEMA RENINA-ANGIOTENSINA, JOVENS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SZCZURKOWSKA, Patrycja et al. Cardiovascular risk profile in young patients with epilepsy. Journal of Hypertension. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1097/01.hjh.0000746092.16662.b9. Acesso em: 07 nov. 2024. , 2021
APA
Szczurkowska, P., Wolf, J., Polonis, K., Becari, C., Pilarska, E., Hoffmann, M., et al. (2021). Cardiovascular risk profile in young patients with epilepsy. Journal of Hypertension. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1097/01.hjh.0000746092.16662.b9
NLM
Szczurkowska P, Wolf J, Polonis K, Becari C, Pilarska E, Hoffmann M, Chrostowska M, Mazurkiewicz-beldzinska M, Narkiewicz K. Cardiovascular risk profile in young patients with epilepsy [Internet]. Journal of Hypertension. 2021 ; 39 e156.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1097/01.hjh.0000746092.16662.b9
Vancouver
Szczurkowska P, Wolf J, Polonis K, Becari C, Pilarska E, Hoffmann M, Chrostowska M, Mazurkiewicz-beldzinska M, Narkiewicz K. Cardiovascular risk profile in young patients with epilepsy [Internet]. Journal of Hypertension. 2021 ; 39 e156.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1097/01.hjh.0000746092.16662.b9
Artigo de periodico
Telomere length and risk of major adverse cardiac events and cancer in obstructive sleep apnea patients (2019)
Polonis, Katarzyna; Sompalli, Sreeja; Ribeiro, Christiane Becari; Xie, Jiang; Covassin, Naima; Schulte, Phillip J.; Druliner, Brooke R.; Johnson, Ruth A.; Narkiewicz, Krzysztof; Boardman, Lisa A.; Singh, Prachi; Somers, Virend K.
Source: Cells. Unidade: FMRP
Subjects: APNEIA DO SONO TIPO OBSTRUTIVA, TELÔMERO, DOENÇAS CARDIOVASCULARES, NEOPLASIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
POLONIS, Katarzyna et al. Telomere length and risk of major adverse cardiac events and cancer in obstructive sleep apnea patients. Cells, v. 8, n. 5, p. 1-12, 2019Tradução . . Disponível em: https://doi.org/10.3390/cells8050381. Acesso em: 07 nov. 2024.
APA
Polonis, K., Sompalli, S., Ribeiro, C. B., Xie, J., Covassin, N., Schulte, P. J., et al. (2019). Telomere length and risk of major adverse cardiac events and cancer in obstructive sleep apnea patients. Cells, 8( 5), 1-12. doi:10.3390/cells8050381
NLM
Polonis K, Sompalli S, Ribeiro CB, Xie J, Covassin N, Schulte PJ, Druliner BR, Johnson RA, Narkiewicz K, Boardman LA, Singh P, Somers VK. Telomere length and risk of major adverse cardiac events and cancer in obstructive sleep apnea patients [Internet]. Cells. 2019 ; 8( 5): 1-12.[citado 2024 nov. 07 ] Available from: https://doi.org/10.3390/cells8050381
Vancouver
Polonis K, Sompalli S, Ribeiro CB, Xie J, Covassin N, Schulte PJ, Druliner BR, Johnson RA, Narkiewicz K, Boardman LA, Singh P, Somers VK. Telomere length and risk of major adverse cardiac events and cancer in obstructive sleep apnea patients [Internet]. Cells. 2019 ; 8( 5): 1-12.[citado 2024 nov. 07 ] Available from: https://doi.org/10.3390/cells8050381
Artigo de periodico
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial (2017)
Ohman, E. Magnus; Roe, Matthew T.; Steg, P. Gabriel; James, Stefan K.; Povsic, Thomas J.; White, Jennifer; Rockhold, Frank; Plotnikov, Alexei; Mundl, Hardi; Strony, John; Sun, Xiang; Husted, Steen; Tendera, Michal; Montalescot, Gilles; Bahit, M. Cecilia; Ardissino, Diego; Bueno, Héctor; Claeys, Marc J.; Nicolau, Jose C.; Cornel, Jan H.; Goto, Shinya; Kiss, Róbert Gábor; Güray, Ümit; Park, Duk-Woo; Bode, Christoph; Welsh, Robert C.; Gibson, C. Michael
Source: Lancet. Unidade: FM
Subjects: FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, ANTICOAGULANTES, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OHMAN, E. Magnus et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet, v. 389, n. 10081, p. 1799-1808, 2017Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(17)30751-1. Acesso em: 07 nov. 2024.
APA
Ohman, E. M., Roe, M. T., Steg, P. G., James, S. K., Povsic, T. J., White, J., et al. (2017). Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet, 389( 10081), 1799-1808. doi:10.1016/S0140-6736(17)30751-1
NLM
Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, Güray Ü, Park D-W, Bode C, Welsh RC, Gibson CM. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial [Internet]. Lancet. 2017 ; 389( 10081): 1799-1808.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1016/S0140-6736(17)30751-1
Vancouver
Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, Güray Ü, Park D-W, Bode C, Welsh RC, Gibson CM. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial [Internet]. Lancet. 2017 ; 389( 10081): 1799-1808.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1016/S0140-6736(17)30751-1
Artigo de periodico
High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial (2017)
Eisen, Alon; Bonaca, Marc P.; Scirica, Benjamin M.; White, Harvey D.; Tendera, Michal; Dellborg, Mikael; Nicolau, Jose C.; Morais, Joao; Fox, Keith A. A.; Bohula, Erin A.; Murphy, Sabina A.; Braunwald, Eugene; Morrow, David A.
Source: Clinical Chemistry. Unidade: FM
Subjects: BIOMARCADOR, TROPONINA, DOENÇAS CARDIOVASCULARES, ARTERIOSCLEROSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EISEN, Alon et al. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. Clinical Chemistry, v. 63, n. 1, p. 307-315, 2017Tradução . . Disponível em: https://doi.org/10.1373/clinchem.2016.264788. Acesso em: 07 nov. 2024.
APA
Eisen, A., Bonaca, M. P., Scirica, B. M., White, H. D., Tendera, M., Dellborg, M., et al. (2017). High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. Clinical Chemistry, 63( 1), 307-315. doi:10.1373/clinchem.2016.264788
NLM
Eisen A, Bonaca MP, Scirica BM, White HD, Tendera M, Dellborg M, Nicolau JC, Morais J, Fox KAA, Bohula EA, Murphy SA, Braunwald E, Morrow DA. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial [Internet]. Clinical Chemistry. 2017 ; 63( 1): 307-315.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1373/clinchem.2016.264788
Vancouver
Eisen A, Bonaca MP, Scirica BM, White HD, Tendera M, Dellborg M, Nicolau JC, Morais J, Fox KAA, Bohula EA, Murphy SA, Braunwald E, Morrow DA. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial [Internet]. Clinical Chemistry. 2017 ; 63( 1): 307-315.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1373/clinchem.2016.264788
Artigo de periodico
Ezetimibe added to statin therapy after acute coronary syndromes (2015)
Cannon, Christopher P.; Blazing, Michael A.; Giugliano, Robert P.; McCagg, Amy; White, Jennifer A.; Theroux, Pierre; Darius, Harald; Lewis, Basil S.; Ophuis, Ton Oude; Jukema, J. Wouter; Ferrari, Gaetano M. De; Ruzyllo, Witold; De Lucca, Paul; Im, KyungAh; Bohula, Erin A.; Reist, Craig; Wiviott, Stephen D.; Tershakovec, Andrew M.; Musline, Thomas A.; Braunwald, Eugene; Califf, Robert M.; Marin Neto, José Antonio; Schmidt, André
Source: The New England Journal of Medicine. Unidade: FMRP
Subjects: SÍNDROME CORONARIANA AGUDA, TERAPÊUTICA MÉDICA, COLESTEROL, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CANNON, Christopher P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. The New England Journal of Medicine, v. 372, n. 25, p. 2387-2397, 2015Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1410489. Acesso em: 07 nov. 2024.
APA
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., et al. (2015). Ezetimibe added to statin therapy after acute coronary syndromes. The New England Journal of Medicine, 372( 25), 2387-2397. doi:10.1056/NEJMoa1410489
NLM
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, Ferrari GMD, Ruzyllo W, De Lucca P, Im KA, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musline TA, Braunwald E, Califf RM, Marin Neto JA, Schmidt A. Ezetimibe added to statin therapy after acute coronary syndromes [Internet]. The New England Journal of Medicine. 2015 ; 372( 25): 2387-2397.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1056/NEJMoa1410489
Vancouver
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, Ferrari GMD, Ruzyllo W, De Lucca P, Im KA, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musline TA, Braunwald E, Califf RM, Marin Neto JA, Schmidt A. Ezetimibe added to statin therapy after acute coronary syndromes [Internet]. The New England Journal of Medicine. 2015 ; 372( 25): 2387-2397.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1056/NEJMoa1410489

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies

Indexado em

Non normalized affiliation

Countries of institutions of collaboration